Common use of Terms Defined Elsewhere Clause in Contracts

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(d) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(iv) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(r) Apogent Material Contract 3.1(q)(i) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent Preferred Stock 3.1(b)(i) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent SEC Documents 3.1(d)(i) Apogent Shareholder Approval 3.1(c)(iii) Apogent Shareholders’ Meeting 5.1(b) Apogent Significant Subsidiaries 3.1(a)(iii) Apogent Stock Plans 3.1(b)(i) Apogent Subsidiary Organizational Documents 3.1(a)(ii) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(i) Applicable Laws 3.1(g)(ii) Approval 3.1(i)(ii) Articles of Merger 1.3 Benefit Continuation Period 5.11(c) Benefit Plans 3.1(i)(i) CDA 4.2(c)(i) Certificates 2.2(b) Change of Recommendation 4.2(d)(ii) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Effect 8.3(k) Effective Time 1.3 ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(2) Exchange Agent 2.2(a) (a) Exchange Ratio 2.1(a) FDA 3.1(g)(i)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(d) Affiliate 8.3(a) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(ivAlternative Transaction 8.3(b) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(r) Apogent Material Contract 3.1(q)(i) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent Preferred Stock 3.1(b)(i) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent SEC Documents 3.1(d)(i) Apogent Shareholder Approval 3.1(c)(iii) Apogent Shareholders’ Meeting 5.1(b) Apogent Significant Subsidiaries 3.1(a)(iii) Apogent Stock Plans 3.1(b)(i) Apogent Subsidiary Organizational Documents 3.1(a)(ii) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(iAlternative Transaction Proposal 8.3(c) Applicable Laws 3.1(g)(ii3.1(g)(i) Approval 3.1(i)(ii) Articles of Merger 1.3 Benefit Continuation Period 5.11(cAudit 3.1(j)(xi) Benefit Plans 3.1(i)(i) CDA 4.2(c)(iBiogen Preamble Biogen Balance Sheet 3.1(d)(iii) Biogen Benefit Plans 3.1(i)(i) Biogen By-Laws 3.1(a)(ii) Biogen Charter 3.1(a)(ii) Biogen Collaboration 3.1(k)(i) Biogen Collaboration Partner 3.1(k)(i) Biogen Common Stock 2.1 Biogen Defined Contribution Plans 3.1(b)(v) Biogen Designated Directors 5.14(a) Biogen Disclosure Schedule 3.1 Biogen Material Contract 3.1(r)(i) Biogen Option 2.1(d) Biogen Organizational Documents 3.1(a)(ii) Biogen Permits 3.1(g)(i) Biogen Pharmaceutical Products 3.1(k)(i) Biogen Preferred Stock 3.1(b)(i) Biogen Purchase Plans 2.1(d) Biogen Rights 3.1(b)(i) Biogen Rights Agreement 3.1(b)(i) Biogen SEC Documents 3.1(d)(i) Biogen Significant Subsidiaries 3.1(a)(iii) Biogen Stock Plans 3.1(b)(i) Biogen Stockholder Approval 3.1(c)(iii) Biogen Stockholders’ Meeting 5.1(b) Biogen Subsidiary Organizational Documents 3.1(a)(ii) Biogen Termination Fee 7.3(a) Certificates 2.2(b) CDA 4.2(c)(i) Chapter 110F 3.1(n) Change of Recommendation 4.2(d)(ii4.2(d)(i) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Continuing Employees 5.12(c) Contract 8.3(d) Dissenting Holder 2.1(g)(i) Effect 8.3(k8.3(l) Effective Time 1.3 Environmental Laws 8.3(e) Environmental Liabilities 8.3(f) ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(2) Exchange Agent 2.2(a) (a) Exchange Fund 2.2(a) Exchange Ratio 2.1(a) Existing Benefits Commitments 4.1(b)(xi) FDA 3.1(g)(i) FDCA 3.1(g)(i) Form S-4 3.1(e) Funded Retirement Plan 3.1(i)(v) GAAP 3.1(d)(ii) Good Clinical Practice 8.3(g) Good Manufacturing Practice 8.3(h) Governmental Entity 3.1(c)(v) Hazardous Materials 8.3(i) HSR Act 3.1(c)(v)(A) Indemnified Parties 5.5(a) Intellectual Property 8.3(j) IDEC Preamble IDEC 1988 Stock Option Plan 3.2(b)(i) IDEC Balance Sheet 3.2(d)(iii) IDEC Benefit Plans 3.2(i)(i) IDEC By-Laws 3.2(a)(ii) IDEC Certificate of Amendment 1.8 IDEC Charter 3.2(a)(ii) IDEC Charter Amendment 1.8 IDEC Collaboration 3.2(k)(i) IDEC Collaboration Partner 3.2(k)(i) IDEC Common Stock 2.1(a) IDEC Defined Contribution Plans 3.2(b)(v) IDEC Designated Directors 5.14(a) IDEC Disclosure Schedule 3.2 IDEC Material Contract 3.2(r)(i) IDEC Options 3.2(b)(ii) IDEC Organizational Documents 3.2(a)(ii) IDEC Preferred Stock 3.2(b)(i) IDEC Permits 3.2(g)(i) IDEC Pharmaceutical Products 3.2(k)(i) IDEC Purchase Plan 3.2(b)(i) IDEC Rights 3.2(b)(i) IDEC Rights Agreement 3.2(b)(i) IDEC SEC Documents 3.2(d)(i) IDEC Significant Subsidiaries 3.2(a)(iii) IDEC Stock Plans 3.2(b)(i) IDEC Stockholder Approval 3.2(c)(iii) IDEC Stockholders’ Meeting 5.1(b) IDEC Subsidiary Organizational Documents 3.2(a)(ii) IDEC Termination Fee 7.3(b) Joint Proxy Statement 3.1(c)(v)(B)(1) Knowledge 8.3(k) Liens 3.1(a)(iii) Material Adverse Change 8.3(l) Material Adverse Effect 8.3(l) MBCL Recitals Merger Recitals Merger Consideration 2.1(a) Merger Sub Preamble New IDEC Annual Bonus Plan 8.3(m) New IDEC Stock Plan 8.3(n) Outside Date 7.1(b)(i) Permitted Acquisition 4.1(b)(iv) Person 8.3(o) Public Health Service Act 3.1(k)(i) Restraints 6.1(d) Rule 145 Affiliates 5.15 SEC 3.1(a)(iii) Secretary of State 1.3 Section 8.3(r) Agreement 8.3(r) Section 203 3.2(n) Securities Act 3.1(d)(i) Share Issuance Recitals Subsidiary 8.3(p) Superior Proposal 8.3(q) Surviving Corporation 1.1 Tax Authority 3.1(j)(xi) Tax Return 3.1(j)(xi) Taxes 3.1(j)(xi) Transaction Event 8.3(r) Transition Team 5.10(a) Voting Debt 3.1(b)(iii)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(dTerm Section Adjustment Excess Amount 2.4(d) Adjustment Shortfall Amount 2.4(d) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(ivAllocation Dispute 1.5(a) Apogent Benefit Plans 3.1(i)(iAllocation Dispute Notice 1.5(a) Apogent Bylaws 3.1(a)(iiAllocation Resolution Period 1.5(a) Apogent Charter 3.1(a)(iiApproval Motion 5.7(a) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Approval Order 5.7(a)(i) Arbitrator 2.4(b) Assignment and Assumption Agreement 1.3(b) Assumed Contracts 1.1(a)(vi) Assumed Liabilities 1.1(c) Assumed Real Property 3.1(rLeases 1.1(a)(x) Apogent Bankruptcy and Equity Exception 3.3 Bankruptcy Cases Recitals Bankruptcy Code Recitals Bankruptcy Court Recitals Bankruptcy Court Orders 5.7(a)(ii) Benefit Plan 3.11I Bidding Procedures 5.7(a)(ii) Bidding Procedures Order 5.7(a)(ii) ▇▇▇▇ of Sale 2.2(a)(i) Books and Records 5.3(b)(i) Break-Up Fee 7.5(b)(ii) Business Recitals Closing 2.1 Closing Date 2.1 Code 1.5(a) Consent Asset 1.3(c) Conditional Approval Order 7.4(f) D&O Insurance 5.6(a) DinoKing Assumed Liabilities 1.1(c)(iv) DinoKing Insolvency Proceeding Cost 5.18(d) DinoKing Proceeding 5.18 Disclosure Letters Introduction to Article IV Dispute 1.5(b) Escrow Amount 2.3(b) Escrow Funds 2.3(b) Estimated Current Assets 2.3(b) Estimated Current Asset Statement 2.3(b) ERISA 3.11(c) Excluded Assets 1.1(b) Excluded Contracts Recitals Final Allocation Schedule 1.5(a) Final Current Assets 2.4(c) Financial Statements 3.5(a) Good Faith Deposit 1.4(a) Insurance Policies 5.1(b)(xi) Interim Period 5.1(a) Material Contract 3.1(q)(i3.10 Notice of Objection 2.4(a) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r3.12(a) Apogent Outside Date 7.4(j) PacBridge Parties Settlement 5.7(h) Permits 3.1(g)(i3.8(b) Apogent Preferred Stock 3.1(b)(iProposed Allocation Schedule 1.5(a) Apogent Purchase Plan 2.1(dPurchaser Preamble Purchaser Default Termination 1.4(b)(ii) Apogent Restricted Stock Unit 5.11(a)(iiPurchaser Disclosure Letter Introduction to Article IV Real Property 3.12(a) Apogent Rights 3.1(b)(iReal Property Lease Assignments 2.2(a)(iii) Apogent Rights Agreement 3.1(b)(iReal Property Leases 3.12(a) Apogent SEC Documents 3.1(d)(iRegistered Intellectual Property 3.14(a) Apogent Shareholder Approval 3.1(c)(iiiReview Period 2.4(a) Apogent Shareholders’ Meeting 5.1(bRMST Shares 3.2(b) Apogent Significant Subsidiaries 3.1(a)(iiiRMST Securities 3.2(c) Apogent Stock Plans 3.1(b)(iSection 338(h)(10) Apogent Subsidiary Organizational Documents 3.1(a)(iiElection 5.10(d) Apogent Termination Fee 7.3(aSeller Disclosure Letter Introduction to Article III Seller Employees 5.5(b) Apogent Third Party Bidder 7.3(a)(iSellers Preamble Service Provider 3.11(c) Applicable Laws 3.1(g)(iiTitle Insurance Policy 5.16(a) Approval 3.1(i)(ii) Articles of Merger 1.3 Benefit Continuation Period 5.11(c) Benefit Plans 3.1(i)(i) CDA 4.2(c)(i) Certificates 2.2(b) Change of Recommendation 4.2(d)(ii) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Effect 8.3(k) Effective Time 1.3 ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(2) Exchange Agent 2.2(aTransferred Employees 5.5(a) (a) Exchange Ratio 2.1(a) FDA 3.1(g)(i)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(dADs 3.1(g)(ii) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(iv) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(r) Apogent Material Contract 3.1(q)(i) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent Preferred Stock 3.1(b)(i) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent SEC Documents 3.1(d)(i) Apogent Shareholder Approval 3.1(c)(iii) Apogent Shareholders’ Meeting 5.1(b) Apogent Significant Subsidiaries 3.1(a)(iii) Apogent Stock Plans 3.1(b)(i) Apogent Subsidiary Organizational Documents 3.1(a)(ii) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(iAlternative Transaction Proposal 4.2(a) Applicable Laws 3.1(g)(ii) Approval 3.1(i)(iiApproved Retention Plans 4.1(a)(vi) Articles CDA 4.2(a)(ii) Certificate of Merger 1.3 Benefit Continuation Period 5.11(c) Benefit Plans 3.1(i)(i) CDA 4.2(c)(i) Certificates 2.2(b) Change of Recommendation 4.2(d)(ii) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Copyrights 8.3(k) Delta Preamble Delta Aircraft 3.2(q)(i) Delta Aircraft Purchase Contract 3.2(q)(iv) Delta Aircraft Finance Contract 3.2(q)(v) Delta Balance Sheet 3.2(d)(iv) Delta Benefit Plans 3.2(i)(i) Delta By-Laws 3.2(a)(ii) Delta CBAs 3.2(h)(i) Delta Change in Recommendation 7.1(e) Delta Charter 3.2(a)(ii) Delta Common Stock 2.1(a) Delta Continuing Directors 1.7(b) Delta Disclosure Schedule 3.2 Delta Distribution Reserve 3.2(b)(i) Delta Excluded Leased Aircraft 3.2(q)(iii) Delta Foreign Plans 3.2(i)(vi) Delta Intellectual Property Rights 3.2(m) Delta Material Contract 3.2(t)(i) Delta Multiemployer Plan 3.2(i)(v) Delta Lease 3.2(w)(ii) Delta Leased Real Property 3.2(w)(ii) Delta Options 3.2(b)(i) Delta Organizational Documents 3.2(a)(ii) Delta Owned Real Property 3.2(w)(i) Delta Performance Shares 3.2(b)(i) Delta Permits 3.2(g)(i) Delta Plan of Reorganization 3.2(b)(i) Delta Preferred Stock 3.2(b)(i) Delta Restricted Stock 3.2(b)(i) Delta SEC Documents 3.2(d)(i) Delta Slots 3.2(r) Delta Stock Plans 3.2(b)(i) Delta Stockholder Approval Recitals Delta Stockholders’ Meeting 5.1(b) Delta Subsidiary Organizational Documents 3.2(a)(ii) Delta Termination Fee 7.2(b) DGCL Recitals DOT 3.1(c)(v)(B)(2) EC Merger Regulation 3.1(c)(v)(A) Effect 8.3(k8.3(m) Effective Time 1.3 ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(23.1(c)(v)(C)(2) Exchange Agent 2.2(a) (a) Exchange Fund 2.2(a) Exchange Ratio 2.1(a) FDA FAA 3.1(c)(v)(B)(1) FARs 3.1(g)(ii) Form S-4 3.1(e) GAAP 3.1(d)(iii) Governmental Entity 3.1(c)(v) HSR Act 3.1(c)(v)(A) Indemnified Parties 5.4(a) Infringement 3.1(m) IRS 3.1(i)(ii) Joint Proxy Statement 3.1(c)(v)(C)(1) Liens 3.1(a)(iii) Merger Recitals Merger Consideration 2.1(a) Merger Sub Preamble New Plans 5.11(c) Northwest Preamble Northwest Aircraft 3.1(q)(i) Northwest Aircraft Purchase Consent 3.1(q)(iv) Northwest Aircraft Finance Contract 3.1(q)(v) Northwest Balance Sheet 3.1(d)(iv) Northwest Benefit Plans 3.1(i)(i) Northwest By-Laws 3.1(a)(ii) Northwest CBAs 3.1(h)(i) Northwest Change in Recommendation 7.1(f) Northwest Charter 3.1(a)(ii) Northwest Common Stock 2.1 Northwest Continuing Directors 1.7(b) Northwest Disclosure Schedule 3.1 Northwest Distribution Reserve 3.1(b)(i) Northwest Excluded Leased Aircraft 3.1(q)(iii) Northwest Foreign Plan 3.1(i)(vi) Northwest Intellectual Property Rights 3.1(m) Northwest Lease 3.1(v)(ii) Northwest Leased Real Property 3.1(v)(ii) Northwest Material Contract 3.1(t)(i) Northwest Multiemployer Plan 3.1(i)(v) Northwest Option 2.1(d) Northwest Organizational Documents 3.1(a)(ii) Northwest Owned Real Property 3.1(v)(i) Northwest Permits 3.1(g)(i) Northwest Plan of Reorganization 3.1(b)(i) Northwest Preferred Stock 3.1(b)(i) Northwest Rights 3.1(b)(i) Northwest Rights Agreement 3.1(b)(i) Northwest SEC Documents 3.1(d)(i) Northwest Slots 3.1(r) Northwest Stock Plans 3.1(b)(i) Northwest Stock Unit Award 2.1(d) Northwest Stockholder Approval Recitals Northwest Stockholders’ Meeting 5.1(b) Northwest Subsidiary Organizational Documents 3.1(a)(ii) Northwest Termination Fee 7.2(c) Notice of Superior Proposal 4.2(a)(iii) NYSE 3.1(c)(v)(D) Outside Date 7.1(b)(i) Patents 8.3(k) Regulatory Actions 5.3(d) Representatives 4.2(a) Represented Employee 5.12 SEC 3.1(c)(v)(C) Second Request 5.3(e) Securities Act 3.1(d)(i) SOX 3.1(d)(i) Stock Issuance 3.2(c)(i) Surviving Corporation 1.1 Surviving Corporation Employees 5.11(b) Tax Authority 3.1(j) Tax Return 3.1(j) Taxes 3.1(j) Third Party 4.2(a) Trade Secrets 8.3(k) Trademarks 8.3(k) Voting Debt 3.1(b)(iii) WARN Act 3.1(h)(ii)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(d7.2(b) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(iv) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(r) Apogent Material Contract 3.1(q)(i) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent Preferred Stock 3.1(b)(i) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent SEC Documents 3.1(d)(i) Apogent Shareholder Approval 3.1(c)(iii) Apogent Shareholders’ Meeting 5.1(b) Apogent Significant Subsidiaries 3.1(a)(iii) Apogent Stock Plans 3.1(b)(i) Apogent Subsidiary Organizational Documents 3.1(a)(ii) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(iRecitals Alternative Transaction Proposal 4.2(a) Applicable Laws 3.1(g)(ii) Approval 3.1(i)(ii) Articles of Merger 1.3 Benefit Continuation Period 5.11(c) Benefit Plans 3.1(i)(i) CDA 4.2(c)(i) Certificates 2.2(b) Change of Recommendation 4.2(d)(ii) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Effect 8.3(kCompany Recitals Company A Warrants Merger Consideration 2.1(a) Company B Warrants Merger Consideration 2.1(a) Company Benefit Plan 5.12 Company By-Laws 1.7(a) Company Charter 1.7(a) Company Common Stock Recitals Company Warrants 5.1(a) Continuing GigOptix Directors 1.8(b) Continuing Lumera Directors 1.8(b) Creditors’ Laws 3.1(c)(i) Designated Director 1.8(a) DGCL Recitals Effective Time 1.3 Employee Benefit Plan 3.1(i)(i) Environmental Claims 3.1(l)(i) Environmental Permits 3.1(l)(i) ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(21.7(b) Exchange Agent 2.2(a) (a) Exchange Fund 2.2(a) Foreign Benefit Plan 3.1(i)(xv) Form S-4 3.1(e) GAAP 3.1(d) GigOptix Recitals GigOptix Audited Historical Financial Statements 5.4 GigOptix Balance Sheet 3.1(d)(ii) GigOptix Benefit Plan 3.1(d)(ii) GigOptix Certificate of Merger 1.3 GigOptix Certificate 2.2(b) GigOptix Common Stock Merger Consideration 2.1(a) GigOptix Director 1.8(a) GigOptix Disclosure Schedule 3.1 GigOptix Effective Time 1.3 GigOptix Exchange Ratio 2.1(a) FDA GigOptix Financial Statements 3.1(d)(i) GigOptix Indemnified Parties 5.7(a) GigOptix Licenses or Permits 3.1(g)(i) GigOptix Material Contract 3.1(o)(i) GigOptix Member Approval 5.2 GigOptix Membership Units Recitals GigOptix Merger Recitals GigOptix Merger Consideration 2.1(a) GigOptix Operating Agreement 3.1(a)(ii) GigOptix Options 3.1(b)(i) GigOptix Organizational Documents 3.1(a)(ii) GigOptix Plan 3.1(b)(i) GigOptix Subsidiary Organizational Documents 3.1(a)(ii) GigOptix Surviving Company 1.1(a) GigOptix Unaudited Financial Statements 3.1(d)(i) GigOptix Voting Debt 3.1(b)(ii) GigOptix’s Counsel 5.11(c) ILLCA Recitals Improvements 3.1(p) Indemnified Parties 5.7(a) Independent Director 1.8(a) Liens 3.1(a)(iii) Lumera Recitals Lumera Balance Sheet 3.2(d)(iv) Lumera Benefit Plans 3.2(h)(i) Lumera By-Laws 3.2(a)(ii) Lumera Certificate of Merger 1.3 Lumera Certificates 2.2(b) Lumera Charter 3.2(a)(ii) Lumera Common Stock Recitals Lumera Directors 1.8(a) Lumera Disclosure Schedule 3.2 Lumera Effective Time 1.3 Lumera Exchange Ratio 2.1(d) Lumera Indemnified Parties 5.7(a) Lumera Licenses or Permits 3.2(f)(i) Lumera Material Contract 3.2(n) Lumera Merger Recitals Lumera Merger Consideration 2.1(d) Lumera Options 3.2(b)(i) Lumera Organizational Documents 3.2(a)(ii) Lumera Preferred Stock 3.2(b)(i) Lumera SEC Documents 3.2(d)(i) Lumera Stock Plan 3.2(b)(i) Lumera Stockholder Approval 5.1(b) Lumera Stockholders’ Meeting 5.1(b) Lumera Subsidiary Organizational Documents 3.2(a)(ii) Lumera Surviving Corporation 1.1(b) Lumera Termination Fee 7.2(c) Lumera Third Party Bidder 7.2(c) Lumera Voting Debt 3.2(b)(iii) Lumera Warrants 3.2(b)(i) Lumera’s Counsel 5.11(c) Merger Consideration 2.1(d) Merger Sub G Recitals Merger Sub L Recitals Mergers Recitals Minimum Trading Price Test 2.1(h)(ii) Multiemployer Plan 3.1(i)(v) NASDAQ 2.1(g) New Equity Plan 5.13(b) Outside Date 7.1(b)(i) Parent 5.18 Predecessor Company 3.1 Prospective GigOptix Financial Statements 4.1(c) Proxy Statement 3.1(e) Recommendations Recitals Representatives 4.2(a) SEC 3.1(e) Securities Act 3.1(e) SOX 3.1(k)(ii) Surviving GigOptix Membership Units Recitals Surviving Lumera Common Stock Recitals Tax Representation Letters 5.11(c)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(d) Affiliate 8.3(a) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(ivAlternative Transaction 8.3(b) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(r) Apogent Material Contract 3.1(q)(i) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent Preferred Stock 3.1(b)(i) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent SEC Documents 3.1(d)(i) Apogent Shareholder Approval 3.1(c)(iii) Apogent Shareholders’ Meeting 5.1(b) Apogent Significant Subsidiaries 3.1(a)(iii) Apogent Stock Plans 3.1(b)(i) Apogent Subsidiary Organizational Documents 3.1(a)(ii) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(iAlternative Transaction Proposal 8.3(c) Applicable Laws 3.1(g)(ii3.1(g)(i) Approval 3.1(i)(ii) Articles of Merger 1.3 Benefit Continuation Period 5.11(cAudit 3.1(j)(xi) Benefit Plans 3.1(i)(i) CDA 4.2(c)(iBiogen Preamble Biogen Balance Sheet 3.1(d)(iii) Biogen Benefit Plans 3.1(i)(i) Biogen By-Laws 3.1(a)(ii) Biogen Charter 3.1(a)(ii) Biogen Collaboration 3.1(k)(i) Biogen Collaboration Partner 3.1(k)(i) Biogen Common Stock 2.1 Biogen Defined Contribution Plans 3.1(b)(v) Biogen Designated Directors 5.14(a) Biogen Disclosure Schedule 3.1 Biogen Material Contract 3.1(r)(i) Biogen Option 2.1(d) Biogen Organizational Documents 3.1(a)(ii) Biogen Permits 3.1(g)(i) Biogen Pharmaceutical Products 3.1(k)(i) Biogen Preferred Stock 3.1(b)(i) Biogen Purchase Plans 2.1(d) Biogen Rights 3.1(b)(i) Biogen Rights Agreement 3.1(b)(i) Biogen SEC Documents 3.1(d)(i) Biogen Significant Subsidiaries 3.1(a)(iii) Biogen Stock Plans 3.1(b)(i) Biogen Stockholder Approval 3.1(c)(iii) Biogen Stockholders' Meeting 5.1(b) Biogen Subsidiary Organizational Documents 3.1(a)(ii) Biogen Termination Fee 7.3(a) Certificates 2.2(b) CDA 4.2(c)(i) Chapter 110F 3.1(n) Change of Recommendation 4.2(d)(ii4.2(d)(i) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Continuing Employees 5.12(c) Contract 8.3(d) Dissenting Holder 2.1(g)(i) Effect 8.3(k8.3(l) Effective Time 1.3 Environmental Laws 8.3(e) Environmental Liabilities 8.3(f) ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(2) Exchange Agent 2.2(a) (a) Exchange Fund 2.2(a) Exchange Ratio 2.1(a) Existing Benefits Commitments 4.1(b)(xi) FDA 3.1(g)(i) FDCA 3.1(g)(i) Form S-4 3.1(e) Funded Retirement Plan 3.1(i)(v) GAAP 3.1(d)(ii) Good Clinical Practice 8.3(g) Good Manufacturing Practice 8.3(h) Governmental Entity 3.1(c)(v) Hazardous Materials 8.3(i) HSR Act 3.1(c)(v)(A) Indemnified Parties 5.5(a) Intellectual Property 8.3(j) IDEC Preamble IDEC 1988 Stock Option Plan 3.2(b)(i) IDEC Balance Sheet 3.2(d)(iii) IDEC Benefit Plans 3.2(i)(i) IDEC By-Laws 3.2(a)(ii) IDEC Certificate of Amendment 1.8 IDEC Charter 3.2(a)(ii) IDEC Charter Amendment 1.8 IDEC Collaboration 3.2(k)(i) IDEC Collaboration Partner 3.2(k)(i) IDEC Common Stock 2.1(a) IDEC Defined Contribution Plans 3.2(b)(v) IDEC Designated Directors 5.14(a) IDEC Disclosure Schedule 3.2 IDEC Material Contract 3.2(r)(i) IDEC Options 3.2(b)(ii) IDEC Organizational Documents 3.2(a)(ii) IDEC Preferred Stock 3.2(b)(i) IDEC Permits 3.2(g)(i) IDEC Pharmaceutical Products 3.2(k)(i) IDEC Purchase Plan 3.2(b)(i) IDEC Rights 3.2(b)(i) IDEC Rights Agreement 3.2(b)(i) IDEC SEC Documents 3.2(d)(i) IDEC Significant Subsidiaries 3.2(a)(iii) IDEC Stock Plans 3.2(b)(i) IDEC Stockholder Approval 3.2(c)(iii) IDEC Stockholders' Meeting 5.1(b) IDEC Subsidiary Organizational Documents 3.2(a)(ii) IDEC Termination Fee 7.3(b) Joint Proxy Statement 3.1(c)(v)(B)(1) Knowledge 8.3(k) Liens 3.1(a)(iii) Material Adverse Change 8.3(l) Material Adverse Effect 8.3(l) MBCL Recitals Merger Recitals Merger Consideration 2.1(a) Merger Sub Preamble New IDEC Annual Bonus Plan 8.3(m) New IDEC Stock Plan 8.3(n) Outside Date 7.1(b)(i) Permitted Acquisition 4.1(b)(iv) Person 8.3(o) Public Health Service Act 3.1(k)(i) Restraints 6.1(d) Rule 145 Affiliates 5.15 SEC 3.1(a)(iii) Secretary of State 1.3 Section 8.3(r) Agreement 8.3(r) Section 203 3.2(n) Securities Act 3.1(d)(i) Share Issuance Recitals Subsidiary 8.3(p) Superior Proposal 8.3(q) Surviving Corporation 1.1 Tax Authority 3.1(j)(xi) Tax Return 3.1(j)(xi) Taxes 3.1(j)(xi) Transaction Event 8.3(r) Transition Team 5.10(a) Voting Debt 3.1(b)(iii)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(dADs 3.1(g)(ii) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(iv) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(r) Apogent Material Contract 3.1(q)(i) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent Preferred Stock 3.1(b)(i) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent SEC Documents 3.1(d)(i) Apogent Shareholder Approval 3.1(c)(iii) Apogent Shareholders’ Meeting 5.1(b) Apogent Significant Subsidiaries 3.1(a)(iii) Apogent Stock Plans 3.1(b)(i) Apogent Subsidiary Organizational Documents 3.1(a)(ii) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(iAlternative Transaction Proposal 4.2(a) Applicable Laws 3.1(g)(ii) Approval 3.1(i)(iiApproved Retention Plans 4.1(a)(vi) Articles CDA 4.2(a)(ii) Certificate of Merger 1.3 Benefit Continuation Period 5.11(c) Benefit Plans 3.1(i)(i) CDA 4.2(c)(i) Certificates 2.2(b) Change of Recommendation 4.2(d)(ii) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Copyrights 8.3(k) Delta Preamble Delta Aircraft 3.2(q)(i) Delta Aircraft Purchase Contract 3.2(q)(iv) Delta Aircraft Finance Contract 3.2(q)(v) Delta Balance Sheet 3.2(d)(iv) Delta Benefit Plans 3.2(i)(i) Delta By-Laws 3.2(a)(ii) Delta CBAs 3.2(h)(i) Delta Change in Recommendation 7.1(e) Delta Charter 3.2(a)(ii) Delta Common Stock 2.1(a) Delta Continuing Directors 1.7(b) Delta Disclosure Schedule 3.2 Delta Distribution Reserve 3.2(b)(i) Delta Excluded Leased Aircraft 3.2(q)(iii) Delta Foreign Plans 3.2(i)(vi) Delta Intellectual Property Rights 3.2(m) Delta Material Contract 3.2(t)(i) Delta Multiemployer Plan 3.2(i)(v) Delta Lease 3.2(w)(ii) Delta Leased Real Property 3.2(w)(ii) Delta Options 3.2(b)(i) Delta Organizational Documents 3.2(a)(ii) Delta Owned Real Property 3.2(w)(i) Delta Performance Shares 3.2(b)(i) Delta Permits 3.2(g)(i) Delta Plan of Reorganization 3.2(b)(i) Delta Preferred Stock 3.2(b)(i) Delta Restricted Stock 3.2(b)(i) Delta SEC Documents 3.2(d)(i) Delta Slots 3.2(r) Delta Stock Plans 3.2(b)(i) Delta Stockholder Approval Recitals Delta Stockholders’ Meeting 5.1(b) Delta Subsidiary Organizational Documents 3.2(a)(ii) Delta Termination Fee 7.2(b) DGCL Recitals DOT 3.1(c)(v)(B)(2) EC Merger Regulation 3.1(c)(v)(A) Effect 8.3(k8.3(m) Effective Time 1.3 ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(23.1(c)(v)(C)(2) Exchange Agent 2.2(a) (a) Exchange Fund 2.2(a) Exchange Ratio 2.1(a) FDA FAA 3.1(c)(v)(B)(1) FARs 3.1(g)(ii) Form S-4 3.1(e) GAAP 3.1(d)(iii) Governmental Entity 3.1(c)(v) HSR Act 3.1(c)(v)(A) Indemnified Parties 5.4(a) Infringement 3.1(m) IRS 3.1(i)(ii) Joint Proxy Statement 3.1(c)(v)(C)(1) Liens 3.1(a)(iii) Merger Recitals Merger Consideration 2.1(a) Merger Sub Preamble New Plans 5.11(c) Northwest Preamble Northwest Aircraft 3.1(q)(i) Northwest Aircraft Purchase Consent 3.1(q)(iv) Northwest Aircraft Finance Contract 3.1(q)(v) Northwest Balance Sheet 3.1(d)(iv) Northwest Benefit Plans 3.1(i)(i) Northwest By-Laws 3.1(a)(ii) Northwest CBAs 3.1(h)(i) Northwest Change in Recommendation 7.1(f) Northwest Charter 3.1(a)(ii) Northwest Common Stock 2.1 Northwest Continuing Directors 1.7(b) Northwest Disclosure Schedule 3.1 Northwest Distribution Reserve 3.1(b)(i) Northwest Excluded Leased Aircraft 3.1(q)(iii) Northwest Foreign Plan 3.1(i)(vi) Northwest Intellectual Property Rights 3.1(m) Northwest Lease 3.1(v)(ii) Northwest Leased Real Property 3.1(v)(ii) Northwest Material Contract 3.1(t)(i) Northwest Multiemployer Plan 3.1(i)(v) Northwest Option 2.1(d) Northwest Organizational Documents 3.1(a)(ii) Northwest Owned Real Property 3.1(v)(i) Northwest Permits 3.1(g)(i) ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ of Reorganization 3.1(b)(i) Northwest Preferred Stock 3.1(b)(i) Northwest Rights 3.1(b)(i) Northwest Rights Agreement 3.1(b)(i) Northwest SEC Documents 3.1(d)(i) Northwest Slots 3.1(r) Northwest Stock Plans 3.1(b)(i) Northwest Stock Unit Award 2.1(d) Northwest Stockholder Approval Recitals Northwest Stockholders’ Meeting 5.1(b) Northwest Subsidiary Organizational Documents 3.1(a)(ii) Northwest Termination Fee 7.2(c) Notice of Superior Proposal 4.2(a)(iii) NYSE 3.1(c)(v)(D) Outside Date 7.1(b)(i) Patents 8.3(k) Regulatory Actions 5.3(d) Representatives 4.2(a) Represented Employee 5.12 SEC 3.1(c)(v)(C) Second Request 5.3(e) Securities Act 3.1(d)(i) SOX 3.1(d)(i) Stock Issuance 3.2(c)(i) Surviving Corporation 1.1 Surviving Corporation Employees 5.11(b) Tax Authority 3.1(j) Tax Return 3.1(j) Taxes 3.1(j) Third Party 4.2(a) Trade Secrets 8.3(k) Trademarks 8.3(k) Voting Debt 3.1(b)(iii) WARN Act 3.1(h)(ii)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(dAgent 3.2(a) Agent Agreement 3.2(a) Agreement Preamble Apogent Antitrust Laws 8.2(b) Audited Driveline Financial Statements 8.12(a) Base Premium 8.4(d) Certificate 3.2(b)(ii) Certificate of Merger 2.3 Closing 2.2 Closing Date 2.2 Covered Persons 8.4(a) ▇▇▇▇ Preamble Apogent Balance Sheet 3.1(d)(iv) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent ▇▇▇▇ Board Recitals ▇▇▇▇ Board Recommendation Recitals ▇▇▇▇ Common Stock 2.1 Apogent 6.2(a) ▇▇▇▇ Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(rLetter VI ▇▇▇▇ Equity Interests 6.2(a) Apogent ▇▇▇▇ Financial Statements 6.7(b) ▇▇▇▇ IP Agreements 6.16(b) ▇▇▇▇ Material Contract 3.1(q)(i6.14(b) Apogent Option 2.1(d▇▇▇▇ Permits 6.17(b) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent ▇▇▇▇ Preferred Stock 3.1(b)(i6.2(a) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent ▇▇▇▇ SEC Documents 3.1(d)(i6.7(a) Apogent Shareholder Approval 3.1(c)(iii▇▇▇▇ Transaction Litigation 8.8 Debt Commitment Letter 6.24(a) Apogent Shareholders’ Meeting 5.1(bDivestiture Action 8.2(c) Apogent Significant Subsidiaries 3.1(a)(iiiDriveline Agreements 5.9(a) Apogent Stock Plans 3.1(b)(iDriveline IP Agreements 5.11(b) Apogent Subsidiary Organizational Documents 3.1(a)(iiDriveline Material Contract 5.9(b) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(i) Applicable Laws 3.1(g)(ii) Approval 3.1(i)(ii) Articles of Merger 1.3 Benefit Continuation Period 5.11(c) Benefit Plans 3.1(i)(i) CDA 4.2(c)(i) Certificates 2.2(b) Change of Recommendation 4.2(d)(ii) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Effect 8.3(kDriveline Permit 5.12(b) Effective Time 1.3 ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v2.3 Enforceability Exceptions 4.2(a) Exchange Fund 3.2(a) Excluded Information 8.10(c)(iv) Fee Letter 6.23(a) Financing 6.23(a) GKN Preamble GKN Board Recitals GKN Board Recommendation Recitals GKN Disclosure Letter IV GKN Transaction Litigation 8.8 Indemnification Agreements 8.4(a) Merger 2.1 Merger Consideration 3.1(a)(i) Merger Regulation 9.1(d)(i) Merger Sub Preamble Merger Sub Common Stock 3.1(b) NYSE 4.4 Required Amount 6.23 ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act 3.1(c)(v)(B)(26.7(a) Exchange Agent 2.2(aSpinCo Preamble SpinCo Board 2.6(a)(i) SpinCo Options 3.4(a) SpinCo PSUs 3.4(d) SpinCo RSUs 3.4(c) SpinCo SARs 3.4(b) Surviving Corporation 2.1 Transaction Litigation 8.8 Unaudited Interim Driveline Financial Statements 8.12(b) (a) Exchange Ratio 2.1(a) FDA 3.1(g)(i)